Tickborne Relapsing Fever Caused by Borrelia persica, Uzbekistan and Tajikistan

International audienc

Hepatitis Rebound after Infection with Yellow Fever Virus

In 2018, yellow fever with hepatitis was diagnosed for 2 unvaccinated travelers returning to France from Brazil. Hepatitis persisted for >6 months; liver enzyme levels again increased 2 months after disease onset with no detection of yellow fever virus RNA or other pathogens. Persistent hepatitis with hepatic cytolysis rebound probably resulted from immune response

Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.

International audienceOBJECTIVES: The aims of the study were to assess in patients with advanced HIV disease receiving antiretroviral therapy (ART) intensification with enfuvirtide (i) resistance at virological failure (VF), (ii) impact of baseline tropism on immunovirological response, and (iii) HIV-1 DNA tropism evolution during ART. METHODS: The ANRS 130 APOLLO randomized trial evaluated in naive patients the immunovirological impact of standard ART without (control arm) or with enfuvirtide. Tropism was determined on RNA and DNA by V3-loop sequencing interpreted using the Geno2Pheno algorithm. RESULTS: At baseline the median CD4 cell count was 30 cells/mm(3). Among the 170 patients assessable in this virological substudy, HIV-1 RNA tropism was as follows: 60% of viruses were R5 and 40% were R5X4/X4. HIV-1 DNA tropism was as follows: 54% were R5 and 46% were R5X4/X4. At week 24, 39% and 49% of patients experienced VF in the enfuvirtide and control arms, respectively. In the enfuvirtide arm, only resistance-associated mutations to enfuvirtide were detected. In the control arm, two patients displayed drug-resistant viruses at the time of VF. No impact of baseline tropism was observed on immunovirological response, regardless of the study arm. Among the 25 patients experiencing DNA tropism switch between baseline and week 24, 16 (64%) switched from R5 to R5X4/X4. These latter were mostly successfully suppressed patients receiving enfuvirtide and exhibiting poorer immunological response. CONCLUSIONS: Baseline RNA tropism had no impact on the immunovirological response. Drug resistance mutations were only detected for the fusion inhibitor. Finally, the mechanism of replenishment of the viral cellular reservoir with X4 viruses observed needs to be further analysed

Protection personnelle antivectorielle

Les vecteurs des agents du paludisme ou de la leishmaniose, rencontrés lors de voyages dans les régions à climat chaud, s'ajoutant à la transmission par le moustique tigre (Aedes albopictus) des virus chikungunya et de la dengue dans le sud de la France, ont montré l'intérêt d'une réflexion approfondie sur la protection personnelle antivectorielle. En cas d'épidémie, nos concitoyens se protègent individuellement en se procurant sur le marché tout un arsenal de moyens où le meilleur côtoie le pire. Pour donner à chacun des informations sur l'efficacité et l'innocuité de ces moyens de protection, la Société de médecine des voyages et la Société française de parasitologie ont initié cette étude qui a pris la forme de « Recommandations de bonne pratique », en suivant le schéma élaboré par la Haute Autorité de santé. Cet ouvrage rassemble ainsi toutes les données pertinentes, validées et mises en forme pour être utilisées non seulement par les personnels de santé (médecins, pharmaciens, infirmiers), mais aussi par les agents touristiques ainsi que par les particuliers pour se protéger des nuisances et des maladies à vecteurs qui constituent de préoccupants problèmes de santé publique.A la mémoire de notre collègue Fabrice Legros (1955-2009

Data from NOVAA-test sensitivity and specificity versus PRNT

NOVAA-test is a new screening test for neutralizing antibodies against yellow fever. Percentage of Yellow fever pseudotype allowing VLP culture and titer of neutralization obtained on reference PRNT assay are compared

NOVAA-test results: Percentage of neutralization with 20 sera from patients with PRNT titres ranging from 10 to 80.

<p>Four complementary sera with a previous PRNT results of 40 were diluted 1:4 in order to surround the cut-off for neutralizing antibody detection by PRNT.</p